로딩 중…
지수 로딩 중…
HLB Therapeutics Co.,Ltd.
115450· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,750+10.22%
2026-11-02
Financials
Valuation Metrics
HLB Therapeutics Co.,Ltd.'s Market Cap is ₩2599B. At end of 2025 it was ₩2706B. Ranked #678 of 2,405 in KR market (top 28%), #283 of 1,627 on KOSDAQ (top 17%), #70 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 259.91B KRW | KR#678/2,405 Sec#70/231 |
| Revenue | 64.45B KRW | KR#1,650/2,405 Sec#109/231 |
| Net Income | -18.57B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 220.71B KRW | KR#1,240/2,405 Sec#89/231 |
| Net Assets | 169.07B KRW | KR#1,056/2,405 Sec#74/231 |
| Employees | 95 | KR#1,673/2,405 Sec#133/231 |
| Value | ||
| P/B | 1.54x | KR#1,828/2,405 Sec#130/231 |
| P/S | 4.04x | KR#2,102/2,405 Sec#139/231 |
| FCF Yield | -3.64% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -10.98% | KR#1,958/2,405 Sec#148/231 |
| ROA | -8.41% | KR#2,059/2,405 Sec#154/231 |
| Op. Margin | -14.36% | KR#2,052/2,405 Sec#140/231 |
| Revenue Growth | 5.25% | KR#1,178/2,405 Sec#116/231 |
| Earnings Growth | -195.74% | KR#1,232/2,405 Sec#83/231 |
| Financial Health | ||
| Debt Ratio | 30.54% | KR#596/2,405 Sec#69/231 |
| Total Debt | 36.29B KRW | KR#1,135/2,405 Sec#82/231 |
| FCF | -9.46B KRW | KR#1,683/2,405 Sec#145/231 |
| Cash | 11.20B KRW | KR#1,631/2,405 Sec#139/231 |
| Current Ratio | 0.78x | KR#1,948/2,405 Sec#191/231 |
| Dividend | ||
| Div. Growth | -37.70% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -13.44% | KR#826/2,405 Sec#45/231 |
| 1M Return | 11.34% | KR#92/2,405 Sec#6/231 |
| From 52W High | -33.89% | KR#540/2,405 Sec#35/231 |
| 1Y MDD | -63.54% | KR#1,640/2,405 Sec#135/231 |
| Trading | ||
| Volume | 584,704 shares | KR#128/2,405 Sec#7/231 |
| Trading Value | 1.55B KRW | KR#481/2,405 Sec#45/231 |
| Foreign Own. | 3.69% | KR#1,117/2,405 Sec#102/231 |
| Per Share | ||
| EPS | -196 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,786 KRW | KR#2,118/2,405 Sec#176/231 |
Company Info
CEO 안기홍
Employees 95
Founded 2000
HQ 경기도 성남시, KR
동사는 2000년 설립되어 2013년 코아인더스를 합병해 전자사업에 진출하고, 2014년 신약공동개발계약으로 바이오사업 기반을 마련하였음. 바이오사업은 ReGenTree와 Oblato를 통해 RGN-259와 OKN-007의 글로벌 임상을 진행하며, 콜드체인사업은 온도민감 의약품을 유통·보관·판매하고 있음. 동사는 바이오 중심 기업으로 전환을 추진하고 있으며, 다각적 사업영역 구축을 통해 지속 가능한 경영을 추구하고 있음. HLB테라퓨틱스는 2000년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.